The body muscles of Caenorhabditis elegans extend plasma membrane extensions called muscle arms to the midline motor axons to form the postsynaptic membrane of the neuromuscular junction. Through a screen for muscle arm development defective (Madd) mutants, we previously discovered that the UNC-40/DCC guidance receptor directs muscle arm extension through the Rho-GEF UNC-73. Here, we describe a gene identified through our mutant screen called madd-2, and show that it functions in an UNC-40 pathway. MADD-2 is a C1-TRIM protein and a homolog of human MID1, mutations in which cause Opitz Syndrome. We demonstrate that MADD-2 functions cell autonomously to direct muscle and axon extensions to the ventral midline of worms. Our results suggest that MADD-2 may enhance UNC-40 pathway activity by facilitating an interaction between UNC-40 and UNC-73. The analogous phenotypes that result from MADD-2 and MID1 mutations suggest that C1-TRIM proteins may have a conserved biological role in midline-oriented developmental events.
INTRODUCTION
Spatial cues along the dorsal-ventral circumferential axis are essential in executing the body plan of many animals, including our own. Cues typically accumulate to maxima or minima at borders between the left and right sides of the developing animal, called the dorsal and ventral midlines, respectively (Hao et al., 2001; Kennedy et al., 1994; Kidd et al., 1999; Wadsworth et al., 1996) . Transmembrane receptors at the leading edge of migrating cells, or at the leading edge of axonal growth cones, translate positional information in the cell's environment into directed plasma membrane extension. Several components that guide midline-oriented migrations were discovered using the nematode Caenorhabditis elegans. For example, , and unc-40 mutants were isolated in the first C. elegans forward genetic screen (Brenner, 1974) , and were later recognized as mutations of key genes that guide circumferential cell and growth cone migrations (Hedgecock et al., 1990) . unc-6 encodes a secreted ligand with maximal expression near the ventral midline (Wadsworth et al., 1996) . UNC-5 is a transmembrane receptor of UNC-6/Netrin that acts in concert with UNC-40/deleted in colorectal cancer (DCC), another transmembrane protein, to guide migrating cells and axons away from UNC-6 Hedgecock et al., 1990; Ishii et al., 1992) . Without UNC-5, UNC-40 guides migrations toward sources of UNC-6 near the ventral midline Hedgecock et al., 1990) .
Not only are many of the molecular details of the UNC-6 pathway conserved in more complex animals, but the pathway regulates similar biological events. For example, the vertebrate homolog of UNC-6, called Netrin, is enriched at the ventral floor plate of the developing spinal cord (Serafini et al., , 1996 . UNC-40 has two highly related mammalian Netrin-receptor homologs, called neogenin (Keino-Masu et al., 1996; Vielmetter et al., 1994) and DCC (Fearon et al., 1990) . In a striking analogy to the role of the worm homologs, DCC guides commissural spinal axons toward the source of Netrin, whereas an UNC-5 homolog, called RCM or UNC-5, guides trochlear motor axons away from the source of Netrin Keino-Masu et al., 1996; Leonardo et al., 1997) .
We recently showed that UNC-40 also guides muscle arm extension to the midline of C. elegans (Alexander et al., 2009 ). The body wall muscles (BWMs) of nematodes extend membrane projections, called muscle arms, to the motor axons (Dixon and Roy, 2005; White et al., 1986) . Each muscle arm has an extended stalk and an elaborate terminus that harbors the postsynaptic machinery of neuromuscular junctions (White et al., 1986) . The 95 mononucleated BWM cells of C. elegans are organized into two dorsal and two ventral quadrants that flank the dorsal and ventral midlines, respectively (Sulston and Horvitz, 1977) . Each quadrant is subdivided into a proximal row and a distal row with respect to the nearest midline. The 79 dorsal and ventral (body) BWMs extend muscle arms exclusively to the dorsal and ventral nerve cords, respectively ( Figure 1A ).
Previous work demonstrated that muscle arms are likely guided to the motor axons in a chemotropic fashion (Hall and Hedgecock, 1991; Hedgecock et al., 1990) , which inspired us to use muscle arms as a model system with which to investigate the genetics of guided migration (Dixon et al., 2006; Dixon and Roy, 2005) . In a forward genetic screen for muscle arm development defective (Madd) mutants, we isolated new alleles of unc-40, unc-73, and gex-2 (Alexander et al., 2009) . We demonstrated that UNC-40 is enriched at muscle arm termini, and that it acts cell autonomously to direct muscle arm extension through the conserved Rho guanine nucleotide exchange factor (Rho-GEF) UNC-73B/Trio (Alexander et al., 2009) . The Rho-GEF domain of UNC-73B stimulates Racs (Steven et al., 1998) , which in turn stimulate Arp2/3-mediated actin-based membrane extension via the WAVE complex (Miki et al., 1998) . gex-2 encodes a homolog of the predicted WAVE-actin polymerization complex member SraI/p140 (Soto et al., 2002) .
Here, we present our characterization of madd-2, the largest complementation group isolated from that screen. In addition to extending fewer muscle arms to the midline, madd-2 mutants have errors in both axon guidance and the extension of other muscles to the ventral midline. We discovered that madd-2 functions within the unc-40 pathway to regulate these midlineoriented extensions. We show that MADD-2 binds the transmembrane receptor UNC-40 and the downstream Rho-GEF, UNC-73. Our data suggests that MADD-2 may enhance the activity of the UNC-40 pathway by facilitating the physical interaction between UNC-40 and UNC-73.
RESULTS

madd-2 Encodes a C1-TRIM Protein and Regulates Muscle Arm Extension Cell Autonomously
As part of a forward genetic screen for C. elegans genes required for muscle arm extension (Alexander et al., 2009) , we isolated six recessive alleles (tr64, tr96, tr101, tr103, tr113 , and tr129) of a single complementation group that we called madd-2. Most body muscles of madd-2 mutants extend fewer than half the wild-type number of muscle arms ( Figure 1F ; see Table S1 available online). Mapping of madd-2(tr64) placed it between À19.85 and À19.84 cM on chromosome V. Of the 32 genes within the 0.01 map unit region, we examined 5 candidates and found mutations in the coding sequence of the C39F7.2 gene for 5 of the 6 madd-2 alleles (Figure 2 ). The sixth allele, tr113, is a complex rearrangement within C39F7.2 ( Figure 2B ). tr150, tr162, tr163, tr171, tr187 , and tr189, were recovered in subsequent screens for additional Madd mutants but were not characterized in detail (Figure 2 ; Table S1 ). Also, an in-frame deletion allele of C39F7.2(ok2226) was generated by the C. elegans knockout consortium (Figure 2B) . We previously referred to our six original alleles of C39F7.2 as madd-2 (Alexander et al., 2009 ). Hence, we and the authors of a companion paper (Hao et al., 2010 [this issue of Developmental Cell] ) continue to refer to C39F7.2 as madd-2.
The madd-2 gene encodes the sole member of the C1 subfamily of tripartite motif (TRIM) proteins in the C. elegans genome (Short and Cox, 2006) . The C1 subfamily is defined by an amino (N)-terminal ring finger (RING) domain, two B box (BB) domains, a coiled-coil domain, a COS domain, a fibronectin-type III (FNIII) domain, and a B30.2 domain (Figure 2 ) (Short and Cox, 2006) . Mammals have six genes encoding C1-TRIM proteins (Short and Cox, 2006 ), yet there is no evidence for a common biological or biochemical role of the members of the C1 subfamily of TRIM proteins. The most extensively characterized C1-TRIM is MID1/TRIM18, which regulates midline development in humans (Quaderi et al., 1997) . MID1 dimers associate with microtubules, polyubiquitinate the catalytic subunit of microtubule-associated protein phosphatase 2A (PP2Ac), and target PP2Ac for degradation by the proteasome Figure S1 ) and by muscle-specific expression of MADD-2A::CFP from the pan-muscle promoter myo-3 (E).
(F and G) The average number of muscle arms per distal muscle of the dorsal right quadrant. Df represents sDf75, a large chromosomal deletion that uncovers madd-2. Standard error of the mean is shown. A black or red asterisk indicates a significant difference (p < 0.001) relative to wild-type or madd-2(tr103), respectively. The blue asterisk indicates a significant difference (p < 0.001) relative to both madd-2(tr103)/+ and sDf75/+ heterozygotes. See also Table S1 . (Trockenbacher et al., 2001) . Mutations in MID1 cause Opitz Syndrome, which is characterized by numerous defects along the ventral midline in humans (De Falco et al., 2003) . It is unclear why MID1 mutations result in ventral midline defects. The characterization of 16 madd-2 cDNAs revealed that exon 8 was missing in 12 of the 16 cDNAs. Exon 8 encodes 14 residues that further separate the COS domain from the FNIII domain and is not conserved with other C1-subfamily members (Figure 2) . We refer to the more prevalent isoform as MADD-2A, and to the other form that includes exon 8 as MADD-2B. We found that the muscle arm extension and axon guidance defects of tr103 do not get worse when placed in trans to a deficiency (Figures 1 and 5 ; Table S1 ). Together with the molecular nature of the tr103 allele, our data indicate that tr103 is genetically null.
To test whether madd-2 functions cell autonomously, we expressed MADD-2 in either all BWMs (by using the myo-3 promoter) or only the distal BWMs (by using the him-4 promoter) of tr103 mutants and observed complete rescue of the muscle arm extension defects ( Figure 1G ). By contrast, neuronal expression of MADD-2 failed to rescue the muscle arm extension defects of the madd-2 null mutant ( Figure 1G ). We conclude that madd-2 functions cell autonomously to regulate muscle arm extension.
MADD-2 Localizes to Muscle Arm Termini
To investigate the spatiotemporal expression pattern of madd-2, we created two chromosomally integrated transgenic arrays called trIs31 and trIs32 that express a MADD-2::GFP fusion protein under the control of madd-2 promoter and enhancer elements ( Figure S1 ). trIs31 rescues the muscle arm extension defects of madd-2 mutants ( Figure 1G ), demonstrating that the MADD-2::GFP fusion protein is functional.
The expression pattern of MADD-2::GFP in animals carrying trIs31 was characterized in detail and is similar to the pattern observed in animals carrying trIs32. Weak MADD-2::GFP expression was first observed in the ventral blast cells during late gastrulation, followed by stronger expression in the overlying ventral hypodermal blast cells during enclosure (Figure 3 ). MADD-2::GFP expression can also be seen in myoblasts at the two-fold stage of development and persists in the BWMs throughout the life of the animal. Within the BWMs, MADD-2::GFP is localized to the dense bodies that anchor thin filaments to the extracellular matrix (Lecroisey et al., 2007) ( Figure S2A ). From the three-fold stage of embryonic development, MADD-2::GFP is localized to the right side of the ventral hypodermal ridge and to the left side of the dorsal hypodermal ridge, where the ventral and dorsal major nerve cords, respectively, reside. Transgenic BWMs that are surrounded by nontransgenic cells show nearby localization of MADD-2::GFP at the hypodermal ridge, suggesting that MADD-2 is localized postsynaptically and not within axons ( Figure S2B ). We also expressed CFP-tagged MADD-2 in select body muscles by using the him-4 promoter (Dixon and Roy, 2005) . The him-4 promoter drives expression in the distal BWMs of each quadrant and not within the nervous system. In these transgenic animals, MADD-2::CFP is localized to the dense bodies and the muscle arm termini in a pattern that recapitulates MADD-2::GFP localization in strains carrying trIs31 (Figure 3 ; Figure S2C ). We conclude that MADD-2 is localized postsynaptically at the muscle arm termini. MADD-2::GFP is also expressed in the vulval muscles, the anchor cell, the six ventral uterine precursor cells, the lateral seam cells, and the ray precursor cells and their descendents in males ( Figure 3J ; Figure S3 ). Other ectodermal derivatives that express MADD-2::GFP include the hermaphrodite-specific neurons (HSNs), and some Q cell descendents, including the AVM, PVM, SDQr, and SDQl neurons ( Figures 3I and 3J , and data not shown).
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MADD-2 Likely Functions at the Leading Edge to Regulate Muscle Arm Extension
To investigate MADD-2 domain function in vivo, we systematically deleted the domains of a MADD-2A::CFP fusion protein and examined the function and localization of the resulting mutant proteins in the muscles of living animals. The RING domain of the MADD-2 homolog MID1 functions as an E3 ubiquitin ligase (Trockenbacher et al., 2001 ). Disrupting MADD-2's RING domain through either deletion (MADD-2A(DR)) or the substitution of a pair of cysteines that disrupt the E3 ligase activity of RING domains (MADD-2A(C7S, C10S)) (Didier et al., 2003) abrogated the fusion protein's ability to rescue the muscle arm extension defects of madd-2 null mutants ( Figure 4 ; Table S2 ). However, the subcellular localization pattern of both of these mutant proteins was indistinguishable from that of the full-length control, demonstrating that the The  table to the right summarizes the behavior of the corresponding construct. The ability of the construct to rescue the Madd phenotype of the madd-2(tr103) null mutant is indicated. Here, rescue indicates an average of 3 or more muscle arms for dorsal right muscle 15 (DR15), as opposed to the negative control, which has an average of 1.4 arms for DR15. A construct is considered to have dominant-negative properties if it reduces arm number below an average of 2.2 arms for DR15 in an otherwise wild-type background, which normally extends an average of 3.6 muscle arms. Three independently derived transgenic lines were investigated for the enrichment of MADD-2::CFP to arm termini and dense bodies. All three lines behaved similarly for all constructs. Wildtype and mutant MADD-2::CFP fusion proteins were judged to be enriched at arm termini if obviously more signal and puncta were observed at the termini compared to a uniform distribution of the signal throughout the cytoplasm More details are provided in Table S2 . RING domain is required for MADD-2 function, but is dispensable for its localization (Figure 4) .
In an otherwise wild-type background, the expression of MADD-2A(DR) or MADD-2A(C7S, C10S) induced muscle arm extension defects (Figure 4 ) and did not enhance the Madd phenotype of a madd-2(tr103) null mutant (Table S2 ). This dominant-negative phenotype suggests that the mutant protein is competing with wild-type MADD-2 for binding partners, but is unable to execute its function and consequently debilitates the MADD-2 protein complex. Hence, the MADD-2 domain(s) important for protein-protein interactions might be inferred by determining which MADD-2 domain suppresss the dominant-negative phenotype when deleted in tandem with the RING domain. Fusion proteins lacking the RING domain and BB2 and/or BB1 domains conferred the same dominant-negative phenotype as MADD-2A(DR) (Figure 4 ). However, deleting the coiled-coil domain in tandem with the RING and the two BB domains abolished the dominant-negative effect (Figure 4 ). These results suggest that the coiled-coil domain of MADD-2 mediates an important protein-protein interaction.
The coiled-coil domain of human MID1 mediates homodimerization, which in turn is a prerequisite for its proper subcellular localization (Short et al., 2002) . We found that MADD-2's coiled-coil domain is required for MADD-2 localization to the muscle arm termini. Fusion proteins lacking amino-terminal domains up to the coiled-coil domain were properly localized to the muscle arm termini (Figure 4) . Upon deleting the coiled-coil domain, however, localization to the termini was abolished (Figure 4) . A MADD-2 protein lacking only the coiled-coil domain and the COS domain (into which the coiled-coil domain is predicted to extend) also failed to localize to the muscle arm termini. The coiled-coil and COS domains by themselves could not mediate localization to the muscle arm termini (Figure 4 ; Table S2 ). Consistent with the role of MID1's coiled-coil domain, our results suggest that MADD-2's coiled-coil domain is necessary, but not sufficient, for proper subcellular localization.
To further investigate the role of MADD-2's C-terminal domains, we recreated the tr101(I530N) and tr64(L667F) missense mutations in the FNIII and B30.2 domains of the MADD-2::CFP fusion protein, respectively. As expected, neither of these transgenic fusion proteins rescued the Madd phenotype of tr103 mutants (Figure 4 ). These two fusion proteins also failed to localize to the muscle arm termini, but like all of the MADD-2 fusion proteins, they were localized to the dense bodies. The dense body localization, together with our western analyses ( Figure 4C ), indicates that the mutant proteins were not degraded. Given that the coiled-coil domain, the FNIII domain, and the B30.2 domain were each required for both MADD-2 function and MADD-2 localization to the muscle arm termini, we conclude that MADD-2 likely functions at the leading edge of extending muscle arms to regulate muscle arm extension.
MADD-2 Functions in a UNC-40 Pathway to Direct Cell Extensions to the Midline
Both MADD-2 and UNC-40 function cell autonomously to direct muscle arm extension and localize to muscle arm termini (Alexander et al., 2009 ). We therefore hypothesized that MADD-2 functions in the UNC-40 pathway. We tested this hypothesis by using double-mutant analyses. A failure to enhance the null mutant phenotype of one gene by a second mutant gene that shares the same phenotype is strong evidence that the two genes function in the same pathway; if two genes act in independent pathways to regulate the same process, the defects of the double mutant are expected to greatly exceed those of the single null mutant. However, unc-40 extends very few muscle arms (Alexander et al., 2009) , leaving little room to exhibit dramatic enhancement of the Madd phenotype. We therefore investigated other MADD-2-expressing cells to determine whether madd-2 mutants might have additional phenotypes that would be more amenable for genetic interaction analyses. We discovered that MADD-2 is required in numerous cell and axon extensions to the ventral midline that are described below.
Four contralateral pairs of vulval muscles open the vulval slit during egg laying (Sulston and Horvitz, 1977) . Through mechanisms that are not understood, the ventral side of each developing muscle extends to meet a contralateral homolog at the ventral midline, while the other side attaches to body muscles (Sulston and Horvitz, 1977) (Figure 5A ). A total of 18% of the anterior contralateral vulval muscle pairs in madd-2(tr103) null mutants failed to meet at the midline, a phenotype we call vulval muscle extension (Vme) defective ( Figure 5D ). The missense madd-2 alleles, tr96 and tr101, have less penetrant defects ( Figure 5D ). We also found that 84% of unc-40(n324) null animals and less than 40% of unc-40(ev546) hypomorphic mutants have the Vme phenotype. The madd-2(tr103) null mutation failed to enhance the Vme phenotype of the unc-40(n324) null animals ( Figure 5D ), suggesting that the two genes act in the same pathway. Furthermore, the weak alleles of madd-2 dramatically enhance the Vme phenotype of the unc-40(ev546) hypomorphs, indicating that the relationship between the two genes is not antagonistic.
We next examined the trajectory of the axons of the bilaterally symmetrical pair of HSNs because MADD-2 is expressed in these cells. UNC-40 directs HSN axon extension ventrally in response to the UNC-6/Netrin cue that is secreted near the ventral midline (Adler et al., 2006; Chan et al., 1996; Hedgecock et al., 1990) . Consistent with previous observations, we observed that 56% of the HSN axons on the right side (HSNr) fail to extend to the ventral midline in unc-40 null mutants and instead extend in other directions ( Figure 5H ). Upon examining the madd-2 null mutant, we found that 23% of the HSNr axons fail to extend to the ventral midline. Expression of MADD-2 in neurons, but not muscles, rescued the HSN axon guidance defects ( Figure 5H ), consistent with a cell-autonomous role for MADD-2 in directing HSN axon guidance. We found that the HSN axon guidance defects of both unc-40 null animals and madd-2 null mutants can be enhanced by a mutation in slt-1, which encodes a component of a parallel pathway. By contrast, unc-40 null mutants cannot be enhanced by a null mutation of madd-2 ( Figure 5H ). Similar conclusions were reached with the genetic analyses of the ventrally directed AVM and PVM mechanosensory axons (Figures 5I-5L) . We conclude that madd-2 functions with unc-40 in parallel to the slt-1 pathway to guide the HSN, AVM, and PVM axons to the ventral midline.
MADD-2 Functions Upstream of UNC-40 and UNC-73
We investigated whether MADD-2 functions upstream or downstream of UNC-40 by using an approach similar to that used by others to order gene products relative to UNC-40 in neurons (Gitai et al., 2003; Levy-Strumpf and Culotti, 2007) . We previously found that overexpression of UNC-40 in the BWMs induces ectopic myopodial extensions that can be suppressed by mutations in the downstream Rho-GEF UNC-73 (Alexander et al., 2009 ). Here, we asked whether madd-2(tr103) also suppresses UNC-40::YFP-mediated myopodial extension, and we found no significant difference between the number of myopodial extensions in the madd-2(tr103) null background (5.9 ± 0.5) and the control background (6.2 ± 0.4) (p > 0.05) ( Figure S4 ). Furthermore, we found that muscle-specific overexpression of either UNC-40::YFP or UNC-73B::CFP suppresses the muscle arm extension defect of madd-2(tr103) null mutants (p < 0.001) (Table S1 ). Together with our results showing that madd-2 functions in the unc-40 pathway, these results indicate that MADD-2 functions upstream of UNC-40 and UNC-73 to direct muscle membrane extension.
MADD-2 Physically Interacts with Both UNC-40 and UNC-73
MADD-2 and UNC-73 both function within the UNC-40 pathway to direct muscle arm extension cell autonomously (this work; Alexander et al., 2009) . We therefore investigated the possibility that MADD-2 physically interacts with UNC-40 and UNC-73. First, we examined the subcellular localization of these tagged proteins and found that MADD-2 colocalizes with UNC-40 and UNC-73 at the muscle arm termini (Figures 6A and 6B) . Despite their colocalization, the abundance and localization of any one of these three proteins is independent of the other two ( Figures 6C-6J ). Using the yeast two-hybrid assay, we found that MADD-2 could physically interact with both UNC-40's intracellular domain (ICD) and UNC-73 ( Figure 7A ; Figure S5 ). Furthermore, the addition of UNC-40(ICD) does not disrupt MADD-2's interaction with UNC-73, and the addition of UNC-73 does not disrupt MADD-2's interaction with UNC-40(ICD) in the yeast two-hybrid assay ( Figure 7A ; Figure S5 ). Next, we expressed epitopetagged MADD-2 in the muscles of animals expressing either GFP-tagged UNC-40 or UNC-73 in muscles. Immunoprecipitating MADD-2 coimmunoprecipitated UNC-40 and UNC-73 from (H) The percentage of HSN axons that fail to extend ventrally in the indicated backgrounds. The deficiency (Df) used is sDf75. The ability of MADD-2A to rescue the HSN axon guidance defects of the madd-2(tr103) null mutant was tested by expressing MADD-2A in either the muscles (m), by using the myo-3 promoter, or in neurons (n), by using the unc-119 promoter, from an extrachromosomal array. Two independently derived lines were examined for each array. Statistical comparisons for the rescued lines are made with respect to the madd-2(tr103) null mutant. (I-K) The mechanosensory axons are visualized with the muIs32 transgenic array (Ch'ng et al., 2003) . The AVM is indicated with a white arrowhead, the ALMr is indicated with a blue arrowhead, and other axons at the ventral midline are indicated with a red arrowhead. Anterior is oriented toward the right. The scale bars in (I) and (J) represent 10 mm; the scale bar in (K) represents 5 mm. (L) The percentage of AVM and PVM axons that fail to extend to the ventral midline. The alleles used are the madd-2(tr103) null mutant, the unc-40(n324) null mutant, and the slt-1(ok255) null mutant. Standard error of the mean is shown in all bar graphs. Significant differences (p < 0.05) in phenotype are indicated with asterisks. ns, no significant difference (p > 0.05). See also Figure S4 . the respective worm strains (Figures 7B and 7C ). Additional controls show that MADD-2 and UNC-40 must be expressed in the same animal to coimmunoprecipitate ( Figure 7B ). Muscleexpressed epitope-tagged UNC-40 was also able to coimmunoprecipitate UNC-73 ( Figure 7D ).
Previous work demonstrated that UNC-40 physically interacts with UNC-73 in a yeast two-hybrid assay that employs 2 micron (m)-based vectors (Watari-Goshima et al., 2007) . We found that we could recapitulate this interaction by using the 2 m-based vectors; however, when we used centromeric-based vectors, UNC-40 and UNC-73 did not interact ( Figure 7A ; Figure S5 ). Fewer copies of centromeric-based yeast vectors are maintained per cell compared to 2 m-based vectors and are therefore expected to drive lower levels of protein expression. We tested the idea that MADD-2 might facilitate the inter- action between UNC-40 and UNC-73 by introducing nuclear-localized MADD-2 without fusing it to any GAL4 domains in a centromeric-vector-based three-hybrid assay. We found that MADD-2 facilitated the physical interaction between UNC-40 and UNC-73 ( Figure 7A ; Figure S5 ). We also have preliminary evidence that coimmunoprecipitation of muscle-expressed UNC-40::YFP and native UNC-73 is reduced in madd-2 null mutant animals (data not shown), but reagent availability has hampered our ability to verify these results in a definitive manner. We conclude that MADD-2 may potentiate the physical interaction between the UNC-40 receptor and the downstream Rho-GEF UNC-73.
DISCUSSION
Here, we describe MADD-2, which acts in concert with the UNC-40 transmembrane receptor and the UNC-73 Rho-GEF to guide muscle and axonal extensions to the midline. Several lines of evidence indicate that MADD-2 may act to enhance UNC-40-mediated signal transduction through UNC-73. First, MADD-2 colocalizes with both UNC-40 and UNC-73 at muscle arm termini. Second, epitope-tagged MADD-2 coimmunoprecipitates with epitope-tagged UNC-40 and UNC-73 when expressed in muscle cells. Third, yeast two-and three-hybrid analyses suggest that, at high concentrations, UNC-40 interacts with UNC-73, but that, at lower concentrations, MADD-2 is necessary for the UNC-40-UNC-73 interaction. Fourth, overexpression of either UNC-40 or UNC-73 suppresses the muscle arm extension defects of a madd-2 null mutant, indicating that MADD-2 is not required if the concentration of UNC-40 or UNC-73 is artificially increased in the cell. Finally, the muscle arm extension and axon guidance defects of the madd-2 null mutant are less severe than those of the unc-40 null mutant (unc-73 null mutants are subviable), suggesting that MADD-2 enhances the otherwise nominal activity of the UNC-40 pathway. Together, our observations suggest that MADD-2 may enhance signal transduction through the UNC-40 pathway by facilitating a physical interaction between UNC-40 and UNC-73.
We have previously demonstrated that UNC-73 functions downstream of UNC-40 to direct muscle arm extension (Alexander et al., 2009) . Others have demonstrated that UNC-73 functions upstream of UNC-40 to direct ALM axon extension along the anterior-posterior axis (Levy-Strumpf and Culotti, 2007; Watari-Goshima et al., 2007) . A major distinction between these two observations is that UNC-5 facilitates ALM axonal extension (Levy-Strumpf and Culotti, 2007; Watari-Goshima et al., 2007) , but not muscle arm extension (Alexander et al., 2009) . Hence, the nature of the relationship between UNC-40 and UNC-73 may be dependent on the presence of UNC-5. We can infer that different proteins must facilitate UNC-40 signal transduction through UNC-73 compared to UNC-40 signal transduction through other cytoskeletal modulators. Indeed, MADD-2 appears to be one of these proteins that facilitates only the UNC-5-independent mode of UNC-40 function. For example, the guidance of commissural axons and the distal tip cells, each of which require UNC-40 and UNC-5 (Hedgecock et al., 1990) , does not require MADD-2 (nor can we detect MADD-2 expression in either of these cell types). By contrast, muscle arm extension and HSN, AVM, and PVM axon guidance are facilitated by MADD-2, but not UNC-5 (Alexander et al., 2009; Hedgecock et al., 1990) . Thus, MADD-2 may facilitate UNC-40 signal transduction through UNC-73 in UNC-5-independent guidance events, but may be unnecessary if UNC-40 signals through other cytoskeletal modulators in UNC-5-dependent guidance events.
The RING domain of the MADD-2 homolog MID1 is an E3 ubiquitin ligase that polyubiquitinates PP2Ac and targets it for proteosomal degradation (Trockenbacher et al., 2001) . It is currently unclear whether MADD-2 has enzymatic activity and, if so, whether it has any bearing on the UNC-40 pathway. We have demonstrated that MADD-2's RING domain is required for muscle arm extension, and that a pair of mutations that is commonly used to disrupt the ubiquitin ligase activity of RING domains (C7S, C10S) also disrupts MADD-2 function without altering its localization or abundance. However, the abundance of muscle-expressed CFP-tagged PP2Ac is not altered upon eliminating or increasing MADD-2 abundance (M.A. and P.J.R., unpublished data), indicating that it is unlikely that MADD-2 targets PP2Ac for degradation through polyubiquitination. Furthermore, the subcellular localization and abundance of UNC-40 and UNC-73 do not change in the absence of MADD-2, indicating that it is also unlikely that MADD-2 ubiquitinates its known binding partners. Further investigation is required to determine the function of the RING domain of MADD-2. Despite the apparent difference in the function of the RING domain, there are numerous similarities between MADD-2 and MID1. For example, the coiled-coil domain, the FNIII domain, and the B30.2 domain of MADD-2 and MID1 are all required for proper subcellular localization in both worms and human cells, respectively (Short et al., 2002) . In addition, MADD-2 and MID1 subcellular localization are both dependent on microtubules (M.A. and P.J.R., unpublished data) (Short et al., 2002) . However, the most striking similarity between MADD-2 and MID1 is their loss-of-function phenotypes. In humans with MID1 mutations, numerous tissues along the ventral midline develop incorrectly. Although the nature of the cellular defects that result in ventral midline defects is not known, much of the defective tissue is derived from neural crest cells that undergo an extensive circumferential migration from the dorsal midline (Schweiger and Schneider, 2003) . In worms, numerous cells along the length of the animal require MADD-2 to extend membrane circumferentially to the ventral midline, including BWMs, vulva muscles, the male sex muscles, and the HSN neurons. Many of the molecular mechanisms that guide the migration of vertebrate neural crest cells or their derivatives are similar to those that guide circumferential extensions and migrations in C. elegans (Jiang et al., 2003; Kee et al., 2007) . We therefore speculate that MID1 may act like MADD-2 to regulate an UNC-40-like pathway in mammals. Decreased activity of an UNC-40-like pathway in tissues that normally express MID1 may be at the root of Opitz Syndrome pathology.
EXPERIMENTAL PROCEDURES
Strains, Mapping, and Phenotypic Analyses All worm strains were grown at 20 C by using standard techniques (Brenner, 1974 ) unless otherwise indicated. The following strains were obtained from the CGC: BC3958 (dpy-18(e364)/eT1 III; sDf75 unc-46(e177)/eT1 [let-500(s2165) ]V); CF1665 (muIs32 II); qid-7(mu327) X, GR1366 (mgIs42), NH2447 (ayIs2 IV); RB1741 (C39F7.2(ok2226) V). unc-40(ev546) was a kind gift from Joe Culotti. We found that ev546 carries a G774R missense mutation in the fourth fibronectin type III domain of UNC-40. The tr64 mutation was mapped to a 228 kb region on the left arm of chromosome V using snip-SNP mapping (Wicks et al., 2001) . Candidate genes in the region were examined for polymorphisms by using a SURVEYOR kit (Transgenomic, Inc). Upon detecting polymorphisms in the C39F7.2 gene in madd-2 mutant backgrounds, we sequenced all madd-2 alleles to find the mutated base pairs. Analysis of madd-2 alleles in trans to a deficiency was done by crossing madd-2(tr103)/+; trIs30/+ and madd-2(tr64)/+; trIs30/+ males into sDF75 hermaphrodites and counting muscle arms of fluorescent F1 progeny.
Muscle arm counts were done as previously described (Dixon and Roy, 2005) . The mean and standard error of the mean for Vme, AVM, PVM, and HSN defects were determined by counting defects of 50 animals from 3 independent replicates. A Student's t test analysis was used to determine significance for all counts.
Transgenics
Muscle-specific rescue of madd-2(tr103) was done by injecting 100 ng/ml pPRGS263 (myo-3p::MADD-2A minigene) construct, which directs the expression of MADD-2A cDNA (yk78e9 from Y. Kohara), or 100 ng/ml pPRGS274 (him-4p::MADD-2A::CFP) or pPRGS272 (him-4p::MADD-2B(yk246e12 cDNA)::CFP). pPD133.45 (myo-3p::NLS::CFP::LacZ), a gift from Andrew Fire, was used as a coinjection marker. MADD-2A was expressed neuronally by injecting 100 ng/ml pPRGS407 along with 20 ng/ml of the coinjection marker pPRGS382 . Muscle-specific deletion and mutant MADD-2A::CFP constructs, which were derived from pPRGS274, were injected with the coinjection marker pRF4 (rol-6(su1006) ) at 100 ng/ml each into wild-type (N2) and trIs30; madd-2(tr103) worms to assay localization and functionality, respectively. The pRFGS316 construct was injected at 2 ng/ml to obtain CFP expression levels that were comparable to the other constructs. For each construct, rescue and localization were analyzed in three independently derived lines. The localization of the fusion protein to muscle arm termini and dense bodies as well as the expression level were qualitatively determined. All constructs were verified by sequencing the resulting manipulated DNA. Maps, notes, and sequences are available upon request.
Yeast Two-and Three-Hybrid Analyses Full details of the yeast two-and three-hybrid analyses are given in Figure S5 . The full-length MADD-2A and UNC-73B open reading frames and the cytoplasmic region of UNC-40 (residues K1108-K1415) were used in the assays.
Immunoprecipitation
A total of 350 ml of mixed-stage packed worms were washed thrice with M9 solution and once with PBS, and were then resuspended in 700 ml ice-cold Solubilization buffer (25 mM Tris [pH 7.4], 100 mM NaCl, 1 mM EDTA, 0.25% NP40, 1 mM PMSF, 1 mM Na3VO4, 2.5 mg/ml Pepstatin-A, 10 mM NaF, and 1 protease inhibitor cocktail tablet [Roche] per 10 ml solution). The samples were incubated on ice for 30 min, then subjected to three cycles of flash freezing in liquid nitrogen, partial thawing, and sonnication for 5 s at 7 Watts. Next, the samples were incubated at 4 C with agitation for 30 min and then centrifuged (13,000 rpm, 30 min, 4 C). A BCA assay (Thermo Scientific) was used to measure the protein concentration in the supernatant. A total of 4 mg/ml protein lysate was incubated with either 20 ml packed Antiflag M2 agarose-coupled antibody (Sigma) or 20 ml packed Protein A/G agarose beads (SantaCruz Biotechnology) along with 2 mg polyclonal GFP antibody (GenScript) for 3 hr with agitation at 4 C. The agarose beads were centrifuged and washed five times with 1 ml cold Solubilization buffer. A total of 100 ml 23 Laemmli sample buffer was then added to the beads, and the samples were boiled and analyzed by western blot. The FLAG-immunoprecipitated samples were analyzed by using an anti-GFP polyclonal antibody and an anti-rabbit HRP-conjugated secondary antibody (SantaCruz Biotechnology). The GFP-immunoprecipitated samples were analyzed by using an anti-GFP monoclonal antibody and an anti-mouse HRP-conjugated secondary antibody (SantaCruz Biotechnology). 
